202 related articles for article (PubMed ID: 35632550)
61. Individuals With Weaker Antibody Responses After Booster Immunization Are Prone to Omicron Breakthrough Infections.
Möhlendick B; Čiučiulkaitė I; Elsner C; Anastasiou OE; Trilling M; Wagner B; Zwanziger D; Jöckel KH; Dittmer U; Siffert W
Front Immunol; 2022; 13():907343. PubMed ID: 35812411
[TBL] [Abstract][Full Text] [Related]
62. Anti-Ad26 humoral immunity does not compromise SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac booster vaccination.
Byazrova MG; Astakhova EA; Minnegalieva AR; Sukhova MM; Mikhailov AA; Prilipov AG; Gorchakov AA; Filatov AV
NPJ Vaccines; 2022 Nov; 7(1):145. PubMed ID: 36379998
[TBL] [Abstract][Full Text] [Related]
63. mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1.
Davis-Gardner ME; Lai L; Wali B; Samaha H; Solis D; Lee M; Porter-Morrison A; Hentenaar IT; Yamamoto F; Godbole S; Douek DC; Lee FE; Rouphael N; Moreno A; Pinsky BA; Suthar MS
bioRxiv; 2022 Nov; ():. PubMed ID: 36380757
[TBL] [Abstract][Full Text] [Related]
64. Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern.
Valanparambil R; Carlisle J; Linderman S; Akthar A; Millett RL; Lai L; Chang A; McCook A; Switchenko J; Nasti T; Saini M; Andreas Wieland AW; Manning K; Ellis M; Moore K; Foster S; Floyd K; Davis-Gardner M; Viswanadh Edara V; Patel M; Steur C; Nooka A; Green F; Johns M; O Brein F; Shanmugasundaram U; Zarnitsyna V; Ahmed H; Nyhoff L; Mantus G; Garett M; Edupuganti S; Behra M; Antia R; Wrammert J; Suthar M; Dhodapkar M; Ramalingam S; Ahmed R
medRxiv; 2022 Jan; ():. PubMed ID: 35018383
[TBL] [Abstract][Full Text] [Related]
65. mRNA vaccines elicit potent neutralization against multiple SARS-CoV-2 omicron subvariants and other variants of concern.
Wang G; Shi J; Verma AK; Guan X; Perlman S; Du L
iScience; 2022 Dec; 25(12):105690. PubMed ID: 36471872
[TBL] [Abstract][Full Text] [Related]
66. BNT162b2 Booster Vaccination Induced Immunity against SARS-CoV-2 Variants among Hemodialysis Patients.
Herman-Edelstein M; Ben-Dor N; Agur T; Guetta T; Raiter A; Meisel E; Alkeesh W; Ori Y; Rozen-Zvi B; Zingerman B
Vaccines (Basel); 2022 Jun; 10(6):. PubMed ID: 35746575
[No Abstract] [Full Text] [Related]
67. Booster dose of BNT162b2 after two doses of CoronaVac improves neutralization of SARS-CoV-2 Omicron variant.
Campos GRF; Almeida NBF; Filgueiras PS; Corsini CA; Gomes SVC; de Miranda DAP; de Assis JV; de Souza Silva TB; Alves PA; da Rocha Fernandes G; de Oliveira JG; Rahal P; Grenfell RFQ; Nogueira ML
Commun Med (Lond); 2022; 2():76. PubMed ID: 35784447
[TBL] [Abstract][Full Text] [Related]
68. Assessment of the Humoral Immune Response Following COVID-19 Vaccination in Healthcare Workers: A One Year Longitudinal Study.
Chivu-Economescu M; Vremera T; Ruta SM; Grancea C; Leustean M; Chiriac D; David A; Matei L; Diaconu CC; Gatea A; Ilie C; Radu I; Cornienco AM; Iancu LS; Cirstoiu C; Pop CS; Petru R; Strambu V; Malciolu S; Popescu CP; Florescu SA; Rafila A; Furtunescu FL; Pistol A
Biomedicines; 2022 Jun; 10(7):. PubMed ID: 35884831
[TBL] [Abstract][Full Text] [Related]
69. SARS-CoV-2 variant exposures elicit antibody responses with differential cross-neutralization of established and emerging strains including Delta and Omicron.
Laurie MT; Liu J; Sunshine S; Peng J; Black D; Mitchell AM; Mann SA; Pilarowski G; Zorn KC; Rubio L; Bravo S; Marquez C; Sabatino JJ; Mittl K; Petersen M; Havlir D; DeRisi J
medRxiv; 2021 Dec; ():. PubMed ID: 34981075
[TBL] [Abstract][Full Text] [Related]
70. Affinity of anti-spike antibodies to three major SARS-CoV-2 variants in recipients of three major vaccines.
Macdonald PJ; Schaub JM; Ruan Q; Williams CL; Prostko JC; Tetin SY
Commun Med (Lond); 2022; 2():109. PubMed ID: 36034646
[TBL] [Abstract][Full Text] [Related]
71. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Dejnirattisai W; Huo J; Zhou D; Zahradník J; Supasa P; Liu C; Duyvesteyn HME; Ginn HM; Mentzer AJ; Tuekprakhon A; Nutalai R; Wang B; Dijokaite A; Khan S; Avinoam O; Bahar M; Skelly D; Adele S; Johnson SA; Amini A; Ritter TG; Mason C; Dold C; Pan D; Assadi S; Bellass A; Omo-Dare N; Koeckerling D; Flaxman A; Jenkin D; Aley PK; Voysey M; Costa Clemens SA; Naveca FG; Nascimento V; Nascimento F; Fernandes da Costa C; Resende PC; Pauvolid-Correa A; Siqueira MM; Baillie V; Serafin N; Kwatra G; Da Silva K; Madhi SA; Nunes MC; Malik T; Openshaw PJM; Baillie JK; Semple MG; Townsend AR; Huang KA; Tan TK; Carroll MW; Klenerman P; Barnes E; Dunachie SJ; Constantinides B; Webster H; Crook D; Pollard AJ; Lambe T; ; ; Paterson NG; Williams MA; Hall DR; Fry EE; Mongkolsapaya J; Ren J; Schreiber G; Stuart DI; Screaton GR
Cell; 2022 Feb; 185(3):467-484.e15. PubMed ID: 35081335
[TBL] [Abstract][Full Text] [Related]
72. Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN.
Yu J; Thomas PV; McMahan K; Jacob-Dolan C; Liu J; He X; Hope D; Martinez EJ; Chen WH; Sciacca M; Hachmann NP; Lifton M; Miller J; Powers OC; Hall K; Wu C; Barrett J; Swafford I; Currier JR; King J; Corbitt C; Chang WC; Golub E; Rees PA; Peterson CE; Hajduczki A; Hussin E; Lange C; Gong H; Matyas GR; Rao M; Paquin-Proulx D; Gromowski GD; Lewis MG; Andersen H; Davis-Gardner M; Suthar MS; Michael NL; Bolton DL; Joyce MG; Modjarrad K; Barouch DH
Sci Adv; 2022 Nov; 8(47):eade4433. PubMed ID: 36417525
[TBL] [Abstract][Full Text] [Related]
73. Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S.
Barbeau DJ; Martin JM; Carney E; Dougherty E; Doyle JD; Dermody TS; Hoberman A; Williams JV; Michaels MG; Alcorn JF; Paul Duprex W; McElroy AK
NPJ Vaccines; 2022 Jul; 7(1):77. PubMed ID: 35794181
[TBL] [Abstract][Full Text] [Related]
74. Antibody Response against Circulating Omicron Variants 8 Months after the Third Dose of mRNA Vaccine.
Anichini G; Terrosi C; Gori Savellini G; Gandolfo C; Barbagli F; Carta GA; Fabrizi S; Miceli GB; Cusi MG
Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146590
[TBL] [Abstract][Full Text] [Related]
75. Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection.
Curlin ME; Bates TA; Guzman G; Schoen D; McBride SK; Carpenter SD; Tafesse FG
medRxiv; 2022 Apr; ():. PubMed ID: 35441177
[TBL] [Abstract][Full Text] [Related]
76. The importance of booster vaccination in the context of Omicron wave.
Wei Z; He J; Wang C; Bao J; Leng T; Chen F
Front Immunol; 2022; 13():977972. PubMed ID: 36159796
[TBL] [Abstract][Full Text] [Related]
77. Limited Neutralization of Omicron by Antibodies from the BNT162b2 Vaccination against SARS-CoV-2.
Lanz TV; Brewer RC; Jahanbani S; Robinson WH
Res Sq; 2022 Apr; ():. PubMed ID: 35441169
[TBL] [Abstract][Full Text] [Related]
78. Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice.
Gao FX; Wu RX; Shen MY; Huang JJ; Li TT; Hu C; Luo FY; Song SY; Mu S; Hao YN; Han XJ; Wang YM; Li L; Li SL; Chen Q; Wang W; Jin AS
iScience; 2022 Dec; 25(12):105479. PubMed ID: 36338436
[TBL] [Abstract][Full Text] [Related]
79. Ex Vivo Immune Responsiveness to SARS-CoV-2 Omicron BA.5.1 Following Vaccination with Unmodified mRNA-Vaccine.
Kuechler AS; Heger E; Wirtz M; Weinhold S; Uhrberg M; Boege F; Schulze-Bosse K
Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992182
[TBL] [Abstract][Full Text] [Related]
80. Effectiveness of Inactivated COVID-19 Vaccines against COVID-19 Caused by the SARS-CoV-2 Delta and Omicron Variants: A Retrospective Cohort Study.
Hua Q; Zheng D; Yu B; Tan X; Chen Q; Wang L; Zhang J; Liu Y; Weng H; Cai Y; Xu X; Feng B; Zheng G; Ding B; Guo J; Zhang Z
Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
